Patient Types/Special Populations: Treatment Naïve
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Dolutegravir Based Regimens
STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Dolutegravir Based Regimens
DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
M184V and the GEMINI Studies
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Dolutegravir Based Regimens
M184V and the GEMINI Studies
Andrew Zolopa, MD, VP, Head, North America Medical Affairs
Dolutegravir Based Regimens
Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir
The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir
DTG+3TC: GEMINI 144-Week Data
An Update from HIV GLASGOW 2020
Nneka Nwokolo, Senior Global Medical Director
Dolutegravir Based Regimens
DTG+3TC: GEMINI 144-Week Data
An Update from HIV GLASGOW 2020
Nneka Nwokolo, Senior Global Medical Director
Dolutegravir Based Regimens
DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies
Nneka Nwokolo, Senior Global Medical Director
Dolutegravir Based Regimens
DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies
Nneka Nwokolo, Senior Global Medical Director
Dolutegravir Based Regimens
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Dolutegravir Based Regimens
DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Dolutegravir Based Regimens
Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dolutegravir Based Regimens
Connect with our Medical Experts
Find my ViiV MSL
Easily find the ViiV Medical Science Liaison (MSL) in your area.
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Talk to a Medical Expert
Connect now with a live ViiV Medical Expert.
Contact Us
Chat Live
Get immediate assistance from a ViiV Healthcare Professional.
Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch